acerta pharma pipeline

• Home
• Blog
• About
• Tutorials

In February 2016, AstraZeneca acquired a majority share of Acerta Pharma via a USD $4 billion investment and is a committed partner to the development of these innovative drugs. Acerta Pharma serves as AstraZeneca’s haematology research and development arm. Under the terms of the agreement, AstraZeneca will acquire 55% of the entire issued share capital of Acerta for total consideration of $4.0 billion, comprised of upfront consideration of $2.5 billion and further unconditional consideration of $1.5 billion to be paid either on receipt of the first regulatory approval for acalabrutinib for any indication in the US, or the end of 2018, depending on which is first. Option for AstraZeneca to Acquire Remaining 45% Ownership in Acerta for Up to $3 Billion OSS, TheNetherlands & REDWOOD CITY, CA, USA I December 17, 2015 I Acerta Pharma B.V. (Acerta), a clinical-stage biopharmaceutical company, announced today that it has entered into a definitive agreement with AstraZeneca whereby AstraZeneca will acquire a majority stake in Acerta. Vincera is expected to have approximately$60 million at closing to fund clinical and preclinical development pipeline. AstraZeneca CEO Pascal Soriot is on a mission to almost double the company's revenue to $45 billion by 2023. You need JavaScript enabled to view it. AstraZeneca said it aims to bring six new cancer medicines to patients by 2020, with a pipeline focused on ovarian, lung, breast and blood cancers. addy15130 = addy15130 + 'lamerie' + '.' + 'com'; You need JavaScript enabled to view it. Action Alerts PLUS is a registered trademark of TheStreet, Inc. ... AstraZeneca said it aims to bring six new cancer medicines to patients by 2020, with a pipeline … Phase I/II data showing a favorable safety profile and strong efficacy in relapsed/refractory chronic lymphocytic leukemia patients was presented at the American Society of Hematology Annual Meeting & Exposition in December 2015, with simultaneous publication in the New England Journal of Medicine. The company is also seeking to strengthen its pipeline to make up for a loss in patent protection by the end of 2017 on three key products --  heartburn medication Nexium, Seroquel for schizophrenia, and cholesterol medicine Crestor -- that account for nearly 40% of its revenue. Prior to joining Kronos Bio, she was at Acerta Pharma, a member of the AstraZeneca Group, as Head of Global Regulatory Science. document.getElementById('cloak15130').innerHTML = ''; Acerta Pharma is a member of the AstraZeneca Group and together we work on our combined early oncology pipeline compounds. Prior to joining Mirum, Dr. Tucker served as chief operating officer at Acerta Pharma LLC where he supported the first U.S. approval and launch of Calquence in 2017. document.getElementById('cloak15130').innerHTML += '' + addy15130+'<\/a>'; Company profile page for Acerta Pharma BV including stock price, company news, press releases, executives, board members, and contact information AstraZeneca partners with like-minded science-led companies to advance the discovery and development of therapies to address unmet need. Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer. “We believe AstraZeneca is the best partner to help advance our research to improve patient outcomes across a range of hematologic cancers and solid tumors.”. The options can be exercised at various points in time, conditional on the first approval of acalabrutinib in both the US and Europe and when the extent of the commercial opportunity has been fully established, at a price of approximately $3.0 billion net of certain costs and payments incurred by AstraZeneca and net of agreed future adjusting items, using a pre-agreed pricing mechanism. The U.S. headquarters is in Redwood City, CA. We look forward to working closely with the AstraZeneca team to realize our mutual goal of transforming cancer care.”, “AstraZeneca has a strong track record of leadership in oncology and has shown a commitment to advancing the next generation of important therapeutics,” said Wayne Rothbaum, Executive Chairman of Acerta. AstraZeneca plc AZN confirmed, in response to a speculation, that it is exploring strategic options with Acerta Pharma BV. This email address is being protected from spambots. //-->. This included designing the information architecture, the interactive interfaces, and crafting collateral materials for a fully-tailored booth experience. If AstraZeneca acquires the remaining shares of the company in the future, Acerta would become a wholly-owned subsidiary. Goldman, Sachs & Co. is acting as lead financial advisor and Jefferies LLC is serving as joint financial advisor to Acerta. It is scheduled to publish 2015 full-year results, along with its guidance for 2016, in early February. Because of this intense collaboration with AstraZeneca, Acerta Clinical Operations play a significant role in drug development in early oncology. Upon close of the transaction, Acerta will initially be a majority-owned subsidiary of AstraZeneca. Acalabrutinib (ACP 196) is an orally administered, second generation, agammaglobulinaemia tyrosine kinase inhibitor (also known as Bruton's tyrosine kinase or It was not immediately clear how big a stake the VC holds or whether it is selling out completely or retaining 45% of its holding for now. More than 600 patients have been treated with acalabrutinib monotherapy. The U.K.'s AstraZeneca (AZN) - Get Report announced an agreement Thursday to buy a 55% stake in Acerta Pharma in a $4 billion deal that will give it a potential blockbuster cancer drug, with an option to buy the rest of the company later. Acerta is also developing ACP-319, a novel isoform-selective inhibitor of phosphoinositide 3-kinase (PI3K) delta. Acerta Pharma is a member of the AstraZeneca Group and together we work on our combined early oncology pipeline compounds. In Thursday's statement, Soriot said the Acerta investment "is consistent with our long-term growth and reflects the role targeted business development plays in our business model.". The deal will give AstraZeneca a potential blockbuster cancer drug, and an option to buy the other 45% of the company later for about $3 billion. “AstraZeneca brings tremendous expertise and resources that will help us maximize the potential of acalabrutinib as we continue down multiple development paths in both hematologic malignancies and solid tumors. Collaborating with Acerta helps to accelerate our global clinical development program for APG-2575," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma. In this role, he oversees clinical development, safety operations, safety science, and quality assurance to advance our development pipeline. Ascentage Pharma has developed a robust pipeline of 8 clinical-stage small molecule drug … Acerta’s lead molecule, acalabrutinib (ACP-196), is a selective and potent inhibitor of Btk. AstraZeneca shares were up 1.45% in London at 4,480 pence, for a total market value of around £56.8 billion ($85.4 billion). Thursday's news comes just a day after AstraZeneca unveiled a $575 million deal to buy respiratory drugs owned by Japan's Takeda Pharmaceutical. “We are excited to announce this strategic transaction with AstraZeneca, which is a testament to the value inherent in Acerta and acalabrutinib,” said David Johnson, Chief Executive Officer of Acerta. Dr Hamdy has +20 years of clinical research experience in pharmaceutical drug development, seven of which were in academic medical research. Jennifer was the Global Regulatory Lead for the Calquence (acalabrutinib) US NDA in R/R MCL which was granted accelerated approval in 2017, as well as for subsequent Calquence global filings in R/R MCL as well as CLL/SLL. On Dec 11, 2015, the Wall. AstraZeneca PLC is in advanced talks to pay more than $5 billion for little-known biotech company Acerta Pharma BV and its promising cancer compound, according to people familiar with the … Morgan, Lewis & Bockius and Nauta Dutilh are serving as legal counsel to Acerta. The New England Journal of Medicine recently published positive results of early clinical testing of the drug, which is seen as a rival to Johnson & Johnson (JNJ) - Get Report and AbbVie's The buyer said it expects the acquisition to be "moderately dilutive" to core earnings in the near term. Because of this intense collaboration with AstraZeneca, Acerta Clinical Operations play a significant role in drug development in early oncology. Acerta Pharma Announces Strategic Transaction with AstraZeneca. AstraZeneca to Acquire 55% Ownership of Acerta for $4 Billion Total Cash Consideration, Option for AstraZeneca to Acquire Remaining 45% Ownership in Acerta for Up to $3 Billion. "We are boosting a key area in our comprehensive oncology portfolio with a late-stage, potential best-in-class medicine that could transform treatments for patients across a range of blood cancers," he added. These are being targeted through four key platforms – immuno-oncology, the genetic drivers of cancer and resistance, … Atara Biotherapeutics’s robust, late-stage pipeline features a host of potentially transformative T-cell immunotherapies for cancer, autoimmune and viral diseases. Our broad pipeline of next-generation medicines is focused on four main disease areas - ovarian, lung, breast and haematological cancers. The transaction will be accounted for as a business combination and is expected to be complete by the end of the first quarter of 2016, subject to regulatory and customary closing conditions. OSS, TheNetherlands & REDWOOD CITY, CA, USA I December 17, 2015 I Acerta Pharma B.V. (Acerta), a clinical-stage biopharmaceutical company, announced today that it has entered into a definitive agreement with AstraZeneca whereby AstraZeneca will acquire a majority stake in Acerta. The transaction provides AstraZeneca with Acerta’s potential best-in-class irreversible oral Bruton's tyrosine kinase (Btk) inhibitor, acalabrutinib (ACP-196), currently in Phase III development for B-cell blood cancers and in Phase I/II clinical trials in multiple solid tumors. Acerta's acalabrutinib is being tested as a treatment for various types of leukemia, lymphoma and other cancers. Acerta is based in Oss in the Netherlands, and has its U.S. headquarters in Redwood City, Calif. At least one of its shareholders in a venture capitalist firm, Dutch investor Biogeneration Ventures, which bought into the company in 2013. AstraZeneca plans to complete the Acerta deal by the end of the first quarter and fund the initial $2.5 billion payment from cash and debt. Stockholders of Vincera ... cofounder of Acerta Pharma … Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. AstraZeneca to Buy Stake in Acerta Pharma Deal is latest move by U.K. drugmaker to rebuild its pipeline AstraZeneca is to take a majority stake in a closely held biotech company. In February 2016, AstraZeneca made a multibillion-dollar investment in Acerta Pharma for 55% ownership, driven by the lead investigational Bruton tyrosine kinase (BTK) inhibitor, acalabrutinib and the opportunity to build out its haematology/oncology pipeline. Acerta's blood cancer drug, which is under trial, is projected to have a multi-billion dollar market, the Journal reports. 2013 • Developed ibrutinib from preclinical through Phase 2 in < 3 years • All three Phase 2 studies garnered Break-Through Designation and Accelerated Approvals. Acalabrutinib is a highly selective, irreversible, second generation Btk inhibitor, with approximately 1,000 patients treated to date in clinical studies across the entire development program. //